They detected NRF2 mutations in oesophagus (8/70; 11.4 %), skin (1/17; 6.3 %), lung (10/125; 8.0 %), and larynx (3/23; 13.0 %) cancers, but not in breast cancer (0/95; 0 %) [35]. Here, NFE2L2 is linked to cancer.